181 related articles for article (PubMed ID: 27053347)
21. Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial.
Noronha V; Patil VM; Menon NS; Joshi A; Goud S; More S; Kannan S; Pawar A; Nakti D; Yadav A; Shah S; Mahajan A; Janu A; Kumar R; Tibdewal A; Mummudi N; Agarwal JP; Banavali SD; Prabhash K
Esophagus; 2022 Oct; 19(4):670-682. PubMed ID: 35614161
[TBL] [Abstract][Full Text] [Related]
22. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
24. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
26. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Boland PM; Meyer JE; Berger AC; Cohen SJ; Neuman T; Cooper HS; Olszanski AJ; Davey M; Cheng JD; Lebenthal A; Burtness BA; Scott WJ; Astsaturov IA
Am J Clin Oncol; 2017 Aug; 40(4):393-398. PubMed ID: 26986978
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
29. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
[TBL] [Abstract][Full Text] [Related]
30. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
33. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Van Echo DA; Haddad R; Jacobs MC; Levy S; Gray WC; Ord RA; Conley BA
Cancer; 2001 Feb; 91(3):548-54. PubMed ID: 11169937
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer.
van Ruler MA; Peters FP; Slingerland M; Fiocco M; Grootenboers DA; Vulink AJ; Marijnen CA; Neelis KJ
Dis Esophagus; 2017 Apr; 30(4):1-9. PubMed ID: 28375477
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
36. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
McCormack M; Kadalayil L; Hackshaw A; Hall-Craggs MA; Symonds RP; Warwick V; Simonds H; Fernando I; Hammond M; James L; Feeney A; Ledermann JA
Br J Cancer; 2013 Jun; 108(12):2464-9. PubMed ID: 23695016
[TBL] [Abstract][Full Text] [Related]
38. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
Noronha V; Joshi A; Jandyal S; Jambhekar N; Prabhash K
Med Oncol; 2014 Sep; 31(9):188. PubMed ID: 25148898
[TBL] [Abstract][Full Text] [Related]
39. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X
Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
